The Phase 1/2 open-label, dose-escalation and dose-expansion clinical trial is expected to enroll up to 18 Fabry disease patients. Dosed the first patient in the Phase 1/2 clinical trial of 4D-310 for the treatment of Fabry disease in March 2021.With the proceeds from our IPO, we raised the capital necessary to expand our vision for developing transformative next-generation gene therapies in multiple therapeutic areas for both rare and large market diseases.” In addition, we strengthened our leadership team and corporate governance, with the addition of key clinical development executives and four experienced board members, including our Executive Chairman John Milligan, Ph.D. “We transitioned into a clinical-stage company, with three product candidates currently in clinical development: 4D-125 for X-linked retinitis pigmentosa, 4D-110 for choroideremia, and 4D-310 for Fabry disease. “2020 was a transformational year for 4D Molecular Therapeutics,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. Cash and cash equivalents of approximately $277M as of Dec 31, 2020ĮMERYVILLE, Calif., Ma(GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the year ended Decemand provided operational highlights. Intravitreal product candidate 4D-150 for the treatment of wet AMD and DME on track to initiate clinical trial in the second half of 2021 Intravitreal product candidates, 4D-125 for the treatment of XLRP and 4D-110 for the treatment of choroideremia, completed dose escalation portion of Phase 1/2 clinical trials (n=12 patients) ĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000E Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000 Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell Microcap Growth IndexĤD Molecular Therapeutics, Inc.- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease are subject to a Lock-Up Agreement Ending on. Ĭertain Common Stock of 4D Molecular Therapeutics, Inc. Ĭertain Options of 4D Molecular Therapeutics, Inc. ![]() ![]() Enter into License Agreement to Use 4Dmt's Proprietary Intravitreal R100 Vector for Rare Ophthalmic TargetsĬhardan Initiates 4D Molecular Therapeutics With Buy Rating, $30 Price TargetĬertain Warrants of 4D Molecular Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023ĤD Molecular Says Interim Data of 4D-150 Trial Shows Clinical Activity, Favorable Safety Profile in Wet Age-Related Macular Degeneration PatientsĤDMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023ĤD Molecular Completes Enrollment of Phase 2 Trial in Patients with Wet Age-Related Macular DegenerationĬhardan Ups Price Target on 4D Molecular Therapeutics to $31 From $30, Maintains Buy RatingĤD Molecular Therapeutics Signs License Agreement With Potential Milestones-Linked Fee Options of up to $942.5 MillionĪstellas Pharma Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |